Projects & Grants
| Research of molecular basis of hematological malignancies and novel biomarkers for targeted cell therapy | |
|---|---|
| Project Id | SGS04/PřF/2023 |
| Main solver | RNDr. Matouš Hrdinka, Ph.D. |
| Period | 1/2023 - 12/2023 |
| Provider | Specifický VŠ výzkum |
| State | solved |
| Anotation | Blood cancer belongs to the most common malignancies. Despite considerable progress in treatment, mainly due to immunotherapy options, this group of diseases is still considered incurable. In addition, repeated relapses are typical for several hemato-oncological diagnoses (e.g., multiple myeloma) due to residual resistant clones in the patient's body. Thus, the main challenge of basic and applied research remains the search for new biomarkers for targeted therapy and seeking an understanding of complex molecular mechanisms responsible for the emergence, development, and resistance of cancer cells. The Blood Cancer Research Group (BCRG) at the Faculty of Medicine OU has been successfully engaged in the clinical, discovery, and applied research of hematological malignancies for a long time and has achieved internationally significant results in this area. In this one-year follow-up project, we want to study several new genes, biomarkers, and mechanisms that may be important for developing new therapeutic strategies based on targeted inhibition and cellular immunotherapy. The project consists of three main aims (1 ? Molecular basis of blood cancer, 2 ? New biomarkers of tumor cells, 3 ? Cell therapies) divided into sub-projects solved by individual students. This project will thus lead not only to acquiring new essential knowledge but also to the further professional development of involved students. The project's outcomes will be at least two publications (Jimp, Q1) and conference contributions. |
